Clinical Trials Logo

Squamous Cell Lung Cancer clinical trials

View clinical trials related to Squamous Cell Lung Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05566223 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

CISH Inactivated TILs in the Treatment of NSCLC

CheckCell-2
Start date: February 2023
Phase: Phase 1/Phase 2
Study type: Interventional

A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Metastatic Non-small Cell Lung Cancer (NSCLC).

NCT ID: NCT04266730 Not yet recruiting - Clinical trials for Squamous Cell Carcinoma of Head and Neck

Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

PANDA-VAC
Start date: August 22, 2024
Phase: Phase 1
Study type: Interventional

This is a single center, open-label phase I clinical trial designed to determine the safety of personalized and adjusted neoantigen peptide vaccine (PANDA-VAC) administered concurrently with pembrolizumab in subjects with advanced squamous non-small cell lung cancer (NSCLC) or squamous cell carcinoma of head and neck (SCCHN).